Daily 670 nm PBM inhibited diabetes-induced RGC death, improved ERG 50%, and prevented leukostasis/ICAM-1 expression through anti-oxidative/anti-inflammatory pathways.
Photobiomodulation (LLLT) simultaneously targets multiple AMD hallmarks—mitochondrial function, inflammation, oxidative stress, vascular health—as multi-pathway therapy.
670 nm light increased mitochondrial membrane potential and reduced age-related retinal inflammation via metabolic enhancement.
670 nm reduced pathological neovascularization in oxygen-induced retinopathy models, offering novel preventive approach for retinopathy of prematurity.
Two-year follow-up showed sustained visual improvements and slowed AMD progression with LLLT, confirming durable disease-modifying effects without adverse events.
PBM preconditioning protected photoreceptors from light-induced damage, preserving structure and function through enhanced cellular resilience.
670 nm preserved photoreceptor function and slowed degeneration in P23H retinitis pigmentosa model through mitochondrial redox state preservation.
LLLT improved visual acuity 2-3 lines in adolescent and adult amblyopia patients, challenging conventional age-limited treatment windows with sustained effects.
670 nm reduced complement C3 deposition and pathway activation in retinal degeneration, attenuating inflammation and enhancing photoreceptor preservation.
NIR photobiomodulation is protective against bright-light-induced retinal degeneration, even when NIR treatment is applied after exposure to light.
